Company intelligence
Biomay
Pharmaceutical Manufacturing
Vienna, AT
68 employees
Founded 1984
6 public signals
About Biomay
Biomay is a GMP manufacturer for plasmid DNA, mRNA and recombinant proteins. We are both technology focused and quality oriented. Our clients appreciate Biomay’s flexibility and reliability. From gene construction to market supply: Biomay delivers for the success of its clients.
Verified activity
Signals from Biomay
6 published signals
Research & Knowledge
Biomay evaluated post-thaw quality of mRNA-LNPs formulations without or with 10% sucrose using 10 freeze-thaw cycles in freezers set at -10, -30, or -80 °C.
Reported by May Guo
Research & Knowledge
Biomay published a study showing that Mannose-cholesterol LNPs (MC_LNPs) target GLUT1 for BBB transcytosis and preferential glioblastoma uptake.
Reported by May Guo
Research & Knowledge
Biomay conducted Forced degradation studies (FDSs) to evaluate the effects of temperature, oxidation, hydrolysis, and agitation on mRNA-LNP formulations, revealing hydrolysis-induced degradation of distearoylphosphatidylcholine (DSPC) and rapid oxidation-induced mRNA degradation within LNPs.
Reported by May Guo
Research & Knowledge
Biomay published a study employing dihydrosphingomyelin (DHSM) as the helper lipid in liposomal LNP to improve mRNA-LNP stability and prolong blood circulation lifetime.
Reported by May Guo
Research & Knowledge
Biomay tested agmatine-oleic acid (Agm-oa) among biogenic polyamines for mRNA delivery and found it showed the best overall performance.
Reported by May Guo
Research & Knowledge
Biomay published a paper discovering that the pH-driven fusion process during TFF-mediated solvent exchange plays a predominant role in shaping mRNA-#LNPs properties.
Reported by May Guo